EBElizabeth A. Barnes

Elizabeth A. Barnes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth A. Barnes has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Cristina M. Alvira

    University of California, San Francisco

    2 shared publications
  • David N. Cornfield

    Center for Excellence in Pulmonary Biology, Divisions of Pulmonary, Asthma, and Sleep Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA

    2 shared publications
  • Xibing Che

    Department of Pediatrics, Center for Excellence in Pulmonary Biology, Stanford University, School of Medicine, Stanford, California, United States

    2 shared publications
  • Alida Kindt

    Metabolomics and Analytics Centre, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands; and

    1 shared publication
  • Anne Hilgendorff

    Comprehensive Pneumology Center, Ludwig Maximilian University of Munich, Munich, Germany

    1 shared publication
  • Carsten Knutsen

    Division of Pulmonary, Asthma, and Sleep Medicine, Center for Excellence in Pulmonary Biology, and

    1 shared publication

Latest Publications

  • Open Access

    MicroRNA‐34a‐Dependent Attenuation of Angiogenesis in Right Ventricular Failure

    by Sushma Reddy, Dong‐Qing Hu, Mingming Zhao, Shoko Ichimura, Elizabeth A. Barnes, David N. Cornfield, Miguel A. Alejandre Alcázar, Edda Spiekerkoetter, Giovanni Fajardo, Daniel Bernstein

    Background: The right ventricle (RV) is at risk in patients with complex congenital heart disease involving right‐sided obstructive lesions. We have shown that capillary rarefaction occurs early in the pressure‐loaded RV. Here we test the hypothesis that microRNA (miR)‐34a, which is induced in RV hypertrophy and RV failure (RVF), blocks the hypoxia‐inducible factor‐1α‐vascular endothelial growth factor (VEGF) axis, leading to the attenuated angiogenic response and increased susceptibility to RV failure. Methods and Results: Mice underwent pulmonary artery banding to induce RV hypertrophy and RVF. Capillary rarefaction occurred immediately. Although hypoxia‐inducible factor‐1α expression increased (0.12±0.01 versus 0.22±0.03, P =0.05), VEGF expression decreased (0.61±0.03 versus 0.22±0.05, P =0.01). miR‐34a expression was most upregulated in fibroblasts (4‐fold), but also in cardiomyocytes and endothelial cells (2‐fold). Overexpression of miR‐34a in endothelial cells increased cell senescence (10±3% versus 22±2%, P <0.05) by suppressing sirtulin 1 expression, and decreased tube formation by 50% via suppression of hypoxia‐inducible factor‐1α, VEGF A, VEGF B, and VEGF receptor 2. miR‐34a was induced by stretch, transforming growth factor‐β1, adrenergic stimulation, and hypoxia in cardiac fibroblasts and cardiomyocytes. In mice with RVF, locked nucleic acid‐antimiR‐34a improved RV shortening fraction and survival half‐time and restored capillarity and VEGF expression. In children with congenital heart disease–related RVF, RV capillarity was decreased and miR‐34a increased 5‐fold. Conclusions: In summary, miR‐34a from fibroblasts, cardiomyocytes, and endothelial cells mediates capillary rarefaction by suppressing the hypoxia‐inducible factor‐1α‐VEGF axis in RV hypertrophy/RVF, raising the potential for anti‐miR‐34a therapeutics in patients with at‐risk RVs.


  • Loss of prolyl hydroxylase 1 and 2 in SM22α-expressing cells prevents Hypoxia-Induced pulmonary hypertension

    by Elizabeth A. Barnes, Reiji Ito, Xibing Che, Cristina M. Alvira, David N. Cornfield

    In a mouse model wherein hypoxia-inducible factor 1 alpha (HIF-1α) is stabilized in vascular smooth muscle cells, we found that HIF-1α regulates vasoconstriction by limiting phosphorylation of myosin light chain and regulates vascular remodeling through p27 induction. These findings highlight a cell-specific role for HIF-1α in the inhibition of pulmonary vasoconstriction and vascular remodeling.


  • Hypoxia-Inducible Factor-1α in SM22α-Expressing Cells Modulates Alveolarization

    by Elizabeth A. Barnes, Carsten Knutsen, Alida Kindt, Xibing Che, Lihua Ying, Eloa Adams, Erika Gonzalez, Prajakta Oak, Anne Hilgendorff, Cristina M. Alvira, et al.

    Worldwide, the incidence of both preterm births and chronic lung disease of infancy, or bronchopulmonary dysplasia, remains high. Infants with bronchopulmonary dysplasia have larger and fewer alveoli, a lung pathology that can persist into adulthood. Although recent data point to a role for hypoxia-inducible factor-1α (HIF-1α) in mediating pulmonary angiogenesis and alveolarization, the cell-specific role of HIF-1α remains incompletely understood. Thus, we hypothesized that HIF-1α, in a distinct subset of mesenchymal cells, mediates postnatal alveolarization. To test the hypothesis, we generated mice with a cell-specific deletion of HIF-1α by crossing SM22α promoter–driven Cre mice with HIF-1αflox/flox mice (SM22α-HIF-1α−/−), determined SM-22α–expressing cell identity using single-cell RNA sequencing, and interrogated samples from preterm infants. Deletion of HIF-1α in SM22α-expressing cells had no effect on lung structure at day 3 of life. However, at 8 days, there were fewer and larger alveoli, a difference that persisted into adulthood. Microvascular density, elastin organization, and peripheral branching of the lung vasculature were decreased in SM22α-HIF-1α−/− mice, compared with control mice. Single-cell RNA sequencing demonstrated that three mesenchymal cell subtypes express SM22α: myofibroblasts, airway smooth muscle cells, and vascular smooth muscle cells. Pulmonary vascular smooth muscle cells from SM22α-HIF-1α−/− mice had decreased angiopoietin-2 expression and, in coculture experiments, a diminished capacity to promote angiogenesis that was rescued by angiopoietin-2. Angiopoietin-2 expression in tracheal aspirates of preterm infants was inversely correlated with overall mechanical ventilation time, a marker of disease severity. We conclude that SM22α-specific HIF-1α expression drives peripheral angiogenesis and alveolarization in the lung, perhaps by promoting angiopoietin-2 expression.